US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a definitive agreement to acquire all outstanding equity of Aliada Therapeutics, Inc., a fellow US firm, for $1.4 billion in cash. The acquisition includes ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of Alzheimer’s disease (AD).
Aliada’s proprietary technology, the Modular Delivery (MODEL) platform, is a groundbreaking method for crossing the blood-brain barrier (BBB) by targeting transferrin and CD98 receptors (TfR and CD98), which is designed to enhance treatment for neurological disorders. ALIA-1758 leverages TfR to transport the 3pE-Aβ antibody across the BBB, facilitating the degradation and removal of amyloid beta plaques, a key pathological feature of Alzheimer’s. The drug is currently undergoing a Phase I clinical trial.
Founded in 2021 with the collaboration of Johnson & Johnson, RA Capital Management, and Raven, RA Capital Management’s incubator, Aliada licensed the MODEL platform developed by J&J scientists. The transaction is anticipated to close in the fourth quarter of 2024.- Flcube.com
